EPHA2/EFNA1 expression in human gastric cancer

Cancer Science

Volumn 96, Issue 1, 2005, Pages 42-47

  Nakamura, Ritsuko ^a   Kataoka, Hideki ^a,b   Sato, Naomi ^c   Kanamori, Masao ^c   Ihara, Megumi ^a   Igarashi, Hisaki ^a   Ravshanov, Sanjar ^a   Wang, You Jie ^d   Li, Zhong You ^e   Shimamura, Takahiro ^a   Kobayashi, Toshihiko ^a   Konno, Hiroyuki ^a   Shinmura, Kazuya ^a   Tanaka, Masamitsu ^f   Sugimura, Haruhiko ^a  

^a HAMAMATSU UNIVERSITY   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

^c Biwako Seikei Sport College   (Japan)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN A1; EPHRIN A2; EPHRIN RECEPTOR A2; ERYTHROPOIETIN; PROTEIN TYROSINE KINASE;

AGE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GASTRECTOMY; GENE OVEREXPRESSION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MALIGNANT TRANSFORMATION; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR VASCULARIZATION; TUMOR VOLUME; WESTERN BLOTTING; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; EPHRIN-A1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RECEPTOR, EPHA2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 20044378481     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00007.x     Document Type: Article

References (32)

1. Bohme B, VandenBos T, Cerretti DP, Park LS, Holtrich U, Rubsamen-Waigmann H, Strebhardt K. Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK- 2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity. J Biol Chem 1996; 271: 24747-52.
2. Mellitzer G, Xu Q, Wilkinson DG. Eph receptors and ephrins restrict cell intermingling and communication. Nature 1999; 400 77-81.
3. George SE, Simokat K, Hardin J, Chisholm AD. The VAB-1 Eph receptor tyrosine kinase functions in neural and epithelial morphogenesis in C. elegans. Cell 1998; 92: 633-43.
4. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial /venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306.
5. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF- alpha-induced angiogenesis. Science 1995; 268: 567-9.
6. Hafner C, Schmitz G, Meyer S, Bataille F, Hart P, Langmann T, Dietmaier W, Landthaler M, Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004; 50: 490-9.
7. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995; 60: 129-36.
8. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301-6.
9. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003; 103: 657-63.
10. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 6043-52.
11. Kao HW, Chen HC, Wu CW, Lin WC. Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids. Br J Cancer 2003; 88: 1058-64.
12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer 1998; 1: 10-24, Available from URL: http://www.jgca.jp/PDFfiles /JCGC-2E.PDF
13. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, Kajimura M, Hanai H, Tanaka M, Sugimura H. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004; 95: 136-41.
14. Wang Y, Ota S, Kataoka H, Wang Y, Ota S, Kataoka H, Kanamori M, Li Z, Band H, Tanaka M, Sugimura H. Negative regulation of EphA2 receptor by Cb1. Biochem Biophys Res Commun 2002; 296: 214-20.
15. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3: 475-86.
16. Flanagan JG, Vanderhaeghen P. The ephrins and Eph receptors in neural development. Annu Rev Neurosci 1998; 21: 309-45.
17. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9: 383-91.
18. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otsuki Y, Kobayashi T, Konno H, Hanai H, Sugimura H. Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 2002; 128: 343-8.
19. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY, Naito Y, Yamada K, Sugimura H, Kino I. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994; 54: 3645-50.
20. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000; 10: 401-11.
21. Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003; 9: 613-18.
22. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001; 72: 1144-8.
23. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41: 275-80.
24. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003; 162: 1037-42.
25. Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003; 163: 2271-6.
26. Tatsumi T, Herrem CJ, Olson WC, Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003; 63: 4481-9.
27. Saito T, Masuda N, Miyazaki T, Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 2004; 11: 605-11.
28. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004; 23: 1448-56.
29. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004; 320: 1096-102.
30. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001; 3: 527-30.
31. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002; 62: 2840-7.
32. Walker-Daniels J, Riese DJ, 2nd, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002; 1: 79-87.